fbpx
Wikipedia

Mirodenafil

Mirodenafil belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first-line treatment for erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving film (50 mg).

Mirodenafil
Legal status
Legal status
  • US: Unscheduled; not FDA-approved
  • Rx-only (KR)
Identifiers
  • 5-Ethyl-3,5-dihydro-2-[5-([4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl)-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one
CAS Number
  • 862189-95-5 Y
PubChem CID
  • 12001014
ChemSpider
  • 10173481 N
UNII
  • 504G362H0H
ChEBI
  • CHEBI:136049
CompTox Dashboard (EPA)
  • DTXSID50881265
Chemical and physical data
FormulaC26H37N5O5S
Molar mass531.67 g·mol−1
3D model (JSmol)
  • Interactive image
  • CCCc1cn(CC)c2c1[nH]c(nc2=O)c1c(OCCC)ccc(c1)S(=O)(=O)N1CCN(CC1)CCO
  • InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33) N
  • Key:MIJFNYMSCFYZNY-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

Several clinical trials were conducted,[1][2][3] but mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.

References edit

  1. ^ Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG (November 2008). "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction". The Journal of Sexual Medicine. 5 (11): 2672–80. doi:10.1111/j.1743-6109.2008.00945.x. PMID 18638004.
  2. ^ Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS (June 2009). "Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea". Clinical Therapeutics. 31 (6): 1234–43. doi:10.1016/j.clinthera.2009.06.008. PMID 19695390.
  3. ^ Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS (December 2009). "The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study". Clinical Therapeutics. 31 (12): 3009–20. doi:10.1016/j.clinthera.2009.12.012. PMID 20110038.

mirodenafil, belongs, drug, class, pde5, inhibitors, which, includes, avanafil, sildenafil, tadalafil, udenafil, vardenafil, first, line, treatment, erectile, dysfunction, developed, chemicals, life, science, mirodenafil, marketed, korea, under, trade, name, m. Mirodenafil belongs to the drug class PDE5 inhibitors which includes avanafil sildenafil tadalafil udenafil and vardenafil and is the first line treatment for erectile dysfunction Developed by SK Chemicals Life Science mirodenafil is marketed in Korea under the trade name Mvix offered both as tablets 50 mg and 100 mg and as orally dissolving film 50 mg MirodenafilLegal statusLegal statusUS Unscheduled not FDA approved Rx only KR IdentifiersIUPAC name 5 Ethyl 3 5 dihydro 2 5 4 2 hydroxyethyl 1 piperazinyl sulfonyl 2 propoxyphenyl 7 propyl 4H pyrrolo 3 2 d pyrimidin 4 oneCAS Number862189 95 5 YPubChem CID12001014ChemSpider10173481 NUNII504G362H0HChEBICHEBI 136049CompTox Dashboard EPA DTXSID50881265Chemical and physical dataFormulaC 26H 37N 5O 5SMolar mass531 67 g mol 13D model JSmol Interactive imageSMILES CCCc1cn CC c2c1 nH c nc2 O c1c OCCC ccc c1 S O O N1CCN CC1 CCOInChI InChI 1S C26H37N5O5S c1 4 7 19 18 30 6 3 24 23 19 27 25 28 26 24 33 21 17 20 8 9 22 21 36 16 5 2 37 34 35 31 12 10 29 11 13 31 14 15 32 h8 9 17 18 32H 4 7 10 16H2 1 3H3 H 27 28 33 NKey MIJFNYMSCFYZNY UHFFFAOYSA N N N Y what is this verify Several clinical trials were conducted 1 2 3 but mirodenafil has not been approved for use in the United States by the U S Food and Drug Administration References edit Paick JS Ahn TY Choi HK Chung WS Kim JJ Kim SC Kim SW Lee SW Min KS Moon KH Park JK Park K Park NC Suh JK Yang DY Jung HG November 2008 Efficacy and safety of mirodenafil a new oral phosphodiesterase type 5 inhibitor for treatment of erectile dysfunction The Journal of Sexual Medicine 5 11 2672 80 doi 10 1111 j 1743 6109 2008 00945 x PMID 18638004 Kim BH Yi S Kim J Lim KS Kim KP Lee B Shin SG Jang IJ Yu KS June 2009 Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil a single dose randomized sequence open label crossover study in healthy male volunteers in Korea Clinical Therapeutics 31 6 1234 43 doi 10 1016 j clinthera 2009 06 008 PMID 19695390 Shin KH Kim BH Kim TE Kim JW Yi S Yoon SH Cho JY Shin SG Jang IJ Yu KS December 2009 The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers an open label one sequence three period three treatment crossover study Clinical Therapeutics 31 12 3009 20 doi 10 1016 j clinthera 2009 12 012 PMID 20110038 nbsp This drug article relating to the genito urinary system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Mirodenafil amp oldid 1135159501, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.